FROM PUBLIC EVENTS · 2026-11-15

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Global approvals · expansion Has signed an agreement extending its oral cancer drug from China to Vietnam.

  • Ten-year exclusive licence and supply agreement for Liporaxel in Vietnam. Source

Roles often seen at this stageBD & licensing · Regulatory affairs · Manufacturing & MSAT

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-15

Daehwa Pharmaceutical

A pharmaceutical maker commercialising Liporaxel, an oral paclitaxel cancer drug, with overseas partners in China, Vietnam and elsewhere.

Liporaxel

Approved

Oral paclitaxel approved and sold in China for gastric cancer, with an exclusive agreement for Vietnam.

Announced

Signed an exclusive licence, supply and distribution agreement for Liporaxel in Vietnam.

Official role guide

Daehwa Pharmaceutical careers

Current availability unconfirmed

Observed 2026-11-15

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 대화제약, 경구용 파클리탁셀 '리포락셀' 베트남 독점 라이선스·공급 계약 ↗라포르시안 · Published 2026-11-04 · Sources checked 2026-11-15 · Original unavailable
  2. 대화제약, 경구용 '리포락셀' 中 품목허가 ↗더바이오 · Published Date unconfirmed · Sources checked 2026-11-15 · Original unavailable